Skip to main content

Varubi Disease Interactions

There are 3 disease interactions with Varubi (rolapitant).

Major

Rolapitant (applies to Varubi) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

No dosage adjustment is necessary when using rolapitant in patients with mild or moderate hepatic impairment. The use of rolapitant should be avoided in patients with severe hepatic impairment as there are no clinical or pharmacokinetic data available for these patients. Close monitoring is recommended.

Switch to professional interaction data

Moderate

Rolapitant (applies to Varubi) lactose intolerance

Moderate Potential Hazard, Moderate plausibility.

Rolapitant tablets contain lactose. Care should be exercised when using this agent in patients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose- containing products, or of glucose-galactose malabsorption.

Switch to professional interaction data

Moderate

Rolapitant (applies to Varubi) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Population pharmacokinetic analyses suggest that no dose adjustment of rolapitant is required in patients with mild or moderate renal impairment. The effect of severe renal impairment on the pharmacokinetics of rolapitant is unknown to determine a dose. This agent has not been studied in patients with end-stage renal disease requiring hemodialysis. Caution is recommended.

Switch to professional interaction data

Varubi drug interactions

There are 223 drug interactions with Varubi (rolapitant).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer